MRA Raises Millions of Dollars for Groundbreaking Melanoma Research
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 5 November 2017 In Allies & Partnerships, Events
Normally, when people are at a Sotheby’s auction, they come to bid on beautiful and rare art. On Nov. 2nd, however, more than 240 people came together at Sotheby’s Headquarters in New York City to raise their paddle in the fight against melanoma. Together, participants raised over $20 million to further advance melanoma research.
Safe and Sound: Balancing Safety with Innovation in American Sunscreens
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 10 October 2017 In Allies & Partnerships, Policy, Prevention
Currently, Americans have access to 16 sunscreen active ingredients approved by the Food and Drug Administration (FDA) to prevent skin cancer. The last time a new OTC (Over the Counter) sunscreen ingredient was added to the FDA sunscreen monograph was 1999. Meanwhile, Europeans have access to 29 sunscreen active ingredients. In the United States there are currently eight new sunscreen ingredients that are pending FDA review, which have been used in Europe – many for over ten years. These new, and potentially better, active ingredients could allow sunscreens to last longer and provide better full spectrum coverage that could help us reverse trends of increasing melanoma incidence in this country. Unlike in Europe where sunscreens are classified as cosmetics, in the United States the FDA is required to evaluate all active ingredients in sunscreens as OTC drugs. Meaning, that all U.S. sunscreen ingredients must be found generally recognized as safe and effective (GRASE) in the same manner as other OTC medications. The FDA says that this is critical to keeping us safe, but is it possible to balance innovation and safety?
Melanoma Research Alliance and the American Cancer Society Forge Research Partnership to Maximize Immunotherapy Benefit to Patients
The Melanoma Research Alliance (MRA) and the American Cancer Society (ACS) are partnering to fund much-needed research aimed at decreasing rare, but serious, side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefit to patients.
LFFM Fundraising Event Again Reaches a Record Setting Year
Nearly 1,000 professionals from the leveraged finance community gathered for the sixth annual Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party raising a record $1.8 million in funds for the Melanoma Research Alliance (MRA), the largest private funder of melanoma research.
MRA and BJ’s Wholesale Club Partner to Launch May Campaign
In today’s dynamic research environment, working as a team is more valuable than ever. This May, in an effort to spotlight Melanoma Awareness month, BJ’s Wholesale Club, a warehouse club operating in 15 states and headquartered in Massachusetts, will launch its first awareness campaign in partnership with MRA to highlight the importance of prevention.